Shortcut to Body
  1. HOME
  2. All KODEX ETFs
  3. Product Details

Asset type Foreign Equity Sector

KODEX SYNTH-US Biotech(185680)

The most effective way to invest in the fast-growing industry, Biotechnology.
KODEX Synth-US bio mainly focuses on USA's biotechnology companies committed to healthier future.

Last data obtained Quotes delayed at least 20 minutes. Market data provided by KOSCOM.

  • Current Price (KRW)


    down 1,590 (-6.05%)

  • iNAV (KRW)


    down 1,586 (-6.08%)

  • Trading Volume (shares)


About Product

* as of Jan 18, 2022

Benchmark Index

S&P Biotechnology Select Industry Index(KRW)

The S&P Biotechnology Select Sector Index seeks to track the Biotechnology sector - stock classifications are based on the Global Industry Classification Standard (GICS).

View index information in detail

Key Facts

Basic Information - Net Assets, Benchmark Index, Gross Expense Ratio, Dividend, Benchmark Index, Base Currency, General Administrator, Trustee
Net Assets 8 (billion) Base Currency KRW
Inception Date October 31, 2013 General
Gross Expense
(AP : 0.020%, Manager fee : 0.190%, Trustee Fee : 0.020%, General Administrator Fee : 0.020%)
Trustee KB Bank
Dividend No dividend distribution Related
  • Carefully consider the Funds' investment objectives, risk factors, and charges and expenses before investing.
  • Collective investment schemes are not insured by the Korea Deposit Insurance Corporation.
  • The performance quoted represents past performance and does not guarantee future results.
  • Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold.
  • Current performance may be lower or higher than the performance quoted.
  • This information is not warranted to be accurate, complete, or timely.
  • Neither KOSCOM nor Samsung Asset Management is responsible for any damages or losses arising from any use of the information on this website.
  • This website is made in the Korean language, and if there shall arise any conflict between the Korean version and any translation thereof,
    including this -English translation, the Korean version shall prevail.